| Literature DB >> 33997613 |
Raquel Mota1,2, Marisa Pinto1,2, Josman Palmeira1,2, Daniela Gonçalves1,2,3, Helena Ferreira1,2.
Abstract
Multidrug-resistant bacteria have been increasingly described in healthcare institutions, however community resistance also seems to be emerging. Escherichia coli an intestinal commensal bacteria, is also a pathogen and represents an important intestinal reservoir of resistance. Our aim was the study of the intestinal colonization and of the persistence of antibiotic resistant intestinal bacteria in healthy university students of Porto, in the north of Portugal. Samples from 30 university students were collected and analysed. Two E. coli isolates were randomly obtained from each student and Gram-negative bacilli resistant to antibiotics were studied. In addition, we evaluated changes in the Gram-negative intestinal colonization of ten university students in a short period of time. Molecular characterization showed a high presence of bla TEM in commensal E. coli . Gram-negative bacteria with intrinsic and extrinsic resistance were isolated, namely Pseudomonas spp., Enterobacter spp. and Pantoea spp. We isolated three ESBL-producing E. coli from two students. These isolates showed bla CTX-M group 1 (n=1), bla CTX-M group 9 (n=2), bla TEM (n=2), bla SHV (n=1) and tetA (n=2) genes. Additionally, they showed specific virulence factors and conjugational transfer of antibiotic resistance and virulence genes. One Pseudomonas spp. isolate resistant to carbapenems was detected colonizing one student. Our results confirm that healthy young adults may be colonized with commensals showing clinically relevant antibiotic resistance mechanisms, creating a risk of silent spread of these bacteria in the community.Entities:
Keywords: Colonization; Healthy young adults; Microbiota; Multidrug-resistant E.coli
Year: 2020 PMID: 33997613 PMCID: PMC8115976 DOI: 10.1099/acmi.0.000182
Source DB: PubMed Journal: Access Microbiol ISSN: 2516-8290
Predominant colonizing bacteria and antibiotic resistance profile in two intestinal commensal randomly selected, in 30 university students of University of Porto (UP)
|
Student ID |
Faculty |
Sex/ Nationality |
Colonies counting |
Predominant bacteria colonizing |
Antibiotic resistance profile in intestinal commensal | |||
|---|---|---|---|---|---|---|---|---|
|
Phenotypic |
Molecular | |||||||
|
β-lactams |
Non-β-lactams |
β-lactams |
Non-β-lactams | |||||
|
1 |
FFUP |
F/Pt |
4,0×106 |
KESC group |
None |
None |
– |
– |
|
2 |
FFUP |
F/Pt |
3,3×108 |
KESC group |
AML |
TE, SXT, C |
|
|
|
3 |
FFUP |
F/Pt |
1,5×107 |
KESC group |
None |
TE |
– |
|
|
4 |
FFUP |
F/Pt |
2,3×107 |
|
None |
None |
– |
– |
|
5 |
FFUP |
F/Sp |
1,1×107 |
|
AML |
TE, C |
|
|
|
6 |
FFUP |
F/Pt |
4,9×107 |
|
AML |
None |
|
– |
|
7 |
FFUP |
F/Pt |
1,7×108 |
|
None |
None |
– |
– |
|
8 |
FFUP |
M/Pt |
4,7×105 |
KESC group |
None |
None |
– |
– |
|
9 |
FFUP |
M/Pt |
4,6×106 |
|
None |
None |
– |
– |
|
10 |
FFUP |
F/Bz |
1,8×108 |
|
None |
None |
– |
– |
|
11 |
FFUP |
F/Sp |
5,9×107 |
|
AML* |
None |
None |
– |
|
12 |
FFUP |
F/Pt |
7,9×107 |
|
AML |
None |
|
– |
|
13 |
FFUP |
F/Geor |
3,1×107 |
KESC group |
AML |
TE, C, CIP*, CN* |
|
|
|
14 |
FFUP |
F/Pt |
1,7×108 |
|
AML |
TE, SXT, C |
|
|
|
15 |
FFUP |
F/Pt |
3,3×107 |
|
AML |
None |
|
– |
|
16 |
FFUP |
M/Bz |
1,3×108 |
|
AML |
None |
|
– |
|
17 |
FFUP |
F/Pt |
1,5×106 |
KESC group |
AML |
CIP |
|
|
|
18 |
FFUP |
F/Pt |
4,3×107 |
|
AML |
None |
|
– |
|
19 |
FFUP |
F/Pt |
4,0×105 |
KESC group |
None |
None |
– |
– |
|
20 |
FFUP |
F/Pt |
1,5×107 |
|
None |
None |
– |
– |
|
21 |
FFUP |
F/Pt |
4,6×107 |
KESC group |
AML |
None |
|
– |
|
22 |
FFUP |
F/Pt |
6,0×106 |
|
None |
None |
– |
– |
|
23 |
FFUP |
F/Pt |
9,6×107 |
|
None |
None |
– |
– |
|
24 |
FFUP |
F/Pt |
1,3×108 |
|
AML*, AMC* |
None |
None |
– |
|
25 |
ICBAS |
M/Pt |
1,4×106 |
|
None |
None |
– |
– |
|
26 |
ICBAS |
M/Pt |
4,3×106 |
KESC group |
None |
None |
– |
– |
|
27 |
ICBAS |
F/Pt |
1,5×108 |
|
None |
None |
– |
– |
|
28 |
ICBAS |
M/Pt |
4,8×105 |
|
AML* |
None |
None |
– |
|
29 |
ICBAS |
M/Pt |
5,2×106 |
|
None |
None |
– |
– |
|
30 |
ICBAS |
F/Pt |
4,3×106 |
|
AML, AMC* |
None |
|
– |
*Isolates with intermediate resistance.
FFUP, Faculty of Pharmacy of University of Porto; ICBAS, Institute of Biomedical Sciences Abel Salazar; F, Female; M, Male; Pt, Portuguese; Sp, Spanish; Bz, Brazilian; Geor, Georgian; AML, amoxicillin; TE, tetracycline; SXT, trimethoprim-sulfamethoxazole; CIP, ciprofloxacin; CN, gentamicin; C, chloramphenicol.
Characteristics of bla CTX-M harbouring isolates recovered from the two university students of FFUP
|
Student ID |
Sex/ age* |
Isolate ID |
Isolation date |
Resistance profile to β-lactam and non-β-lactam antibiotics† |
ESBL genes |
Other β-lactamases |
Resistance to non-β-lactams genes |
Virulence genes‡ |
Phylogenetic group |
|---|---|---|---|---|---|---|---|---|---|
|
2 |
F/ 21 |
2A |
October 2015 |
AML, PRL, CXM§, CTX, ATM§, CAZ§, TET |
|
|
|
|
B1 |
|
24 |
F/ 22 |
24A |
March 2016 |
AML, PRL, CXM, CTX, CPT |
|
– |
– |
|
A |
|
24B|| |
March 2016 |
AML, PRL, CXM, CTX, CPT, TET |
CTX-M group 9 |
TEM |
|
|
B1 | ||
|
24C||, ¶ |
October 2016 |
AML, PRL, CXM, CTX, CPT, TET |
CTX-M group 9 |
TEM |
|
|
D |
*F, Female.
†AML, amoxicillin; PRL, piperacillin; CXM, cefuroxime; CTX, cefotaxime; ATM, aztreonam; CAZ, ceftazidime; CPT, ceftaroline; TET, tetracycline.
‡fimH - type one fimbriae; iutA - ferric aerobactin receptor; fyuA - yersiniabactin receptor; traT - serum survival associated; cvaC - colicin V; underlined - antibiotic resistance genes and virulence genes transferred in conjugation assay; (-) not detected.
§Isolates with intermediate resistance.
||Colonies with mucoid aspect.
¶Isolate recovered after 5 months of the first detection (October 2016).
Follow up results in ten participants. First detection, after 3 months of the first detection (second detection) and after 1 month of the second detection (third detection)
|
Student ID |
First detection |
Second detection |
Third detection | |||
|---|---|---|---|---|---|---|
|
c.f.u. per gram of faeces* |
|
c.f.u. per gram of faeces* |
|
c.f.u. per gram of faeces* |
| |
|
1 |
4.0×106 |
Without resistance |
9.2×106 |
Without resistance |
2.4×108 |
Without resistance |
|
4 |
2.3×107 |
Without resistance |
1.1×108 |
Without resistance |
5.3×106 |
Without resistance |
|
25 |
1.4×106 |
Without resistance |
2.6×105 |
Without resistance |
1.5×105 |
Without resistance |
|
29 |
5.2×106 |
Without resistance |
6.1×107 |
Without resistance |
5.2×106 |
Without resistance |
|
3 |
1.5×107 |
TE | |
1.7×107 |
Without resistance |
1.3×106 |
Without resistance |
|
6 |
4.9×107 |
AML | |
1.6×107 |
Without resistance |
1.7×106 |
Without resistance |
|
15 |
3.3×107 |
AML | AML |
7.1×107 |
Without resistance |
7.9×107 |
AML‡ AML‡ |
|
28 |
4.8×105 |
AML‡ |
1.1×107 |
AML‡ Without resistance |
8.3×106 |
Without resistance |
|
2 |
3.3×108 |
AML, TE, SXT, C | AML, TE | |
9.7×105 |
AML, TE, SXT| blaTEM, Without resistance |
1.0×108 |
AML, TE, SXT | |
|
12 |
7.9×107 |
AML | |
1.5×108 |
AML, TE, CIP, CN SXT | TE | |
1.0×108 |
AML, TE, CIP, CN SXT | |
*Only Gram-negative bacteria were counted.
†From two E. coli isolates randomly selected from each student. When only one profile is presented, this means that both E. coli isolates are the same, phenotypic and molecular.
‡Isolates with intermediate resistance.
AML, amoxicillin; CTX, cefotaxime; TE, tetracycline; SXT, trimethoprim-sulfamethoxazole; CIP, ciprofloxacin; CN, gentamicin; C, chloramphenicol
Background information distribution among participants in absolute number and percent
|
Background data |
Percent/absolute no. | |
|---|---|---|
|
Sex |
Female |
76.7 % (23/30) |
|
Male |
23.3 % (7/30) | |
|
Nationality |
Portuguese |
83.3 % (25/30) |
|
Spanish |
6.7 % (2/30) | |
|
Brazilian |
6.7 % (2/30) | |
|
Georgian |
3.3 % (1/30) | |
|
Predominant alimentation* |
Mediterranic |
92.3 % (24/26) |
|
Raw meat eater |
26.9 % (7/26) | |
|
Vegetarian |
7.7 % (2/26) | |
|
Contact with animals* |
65.4 % (17/26) | |
|
International travel in last year*† |
42.3 % (11/26) | |
|
Gastrointestinal changes in last year* |
23.1 % (6/26) | |
|
Contact with human patients* |
23.1 % (6/26) | |
*Data were extracted from 26 out of 30 questionnaires.
†England, Italy, Spain, France, Brazil, Germany, Netherlands, Denmark, United States of America, Mexico, Hungary, Austria, Egypt.
Description of the changes in the university students that were followed up, after 3 months of the first detection
|
Volunteer no. |
Food changes |
Contact with animals changes |
International travel |
Antibiotic consumption |
Gastrointestinal changes |
Contact with human patients |
|---|---|---|---|---|---|---|
|
|
No |
No |
No |
No |
No |
No |
|
|
No |
No |
No |
No |
No |
Gastrointestinal disease |
|
|
No |
No |
No |
No |
No |
No |
|
|
No |
No |
No |
No |
No |
No |
|
|
No |
No |
No |
Ciprofloxacin (5 days) |
No |
Cancer patient |
|
|
No |
No |
No |
Doxycycline (2 months, continued after follow up) |
No |
No |
|
|
No |
No |
France and Germany (bottled water consumption) |
No |
No |
No |
|
|
No |
No |
Germany and Austria (bottled and public water consumption) |
No |
No |
No |
|
|
Vegetarian |
Increase (canids, cattle, horses) |
No |
No |
No |
No |
|
|
– |
– |
– |
– |
– |
– |
Data were extracted from 9 out of 10 questionnaires.